Skip to main content
SpringerLink
Log in

Approaching Pancreatic Cancer Phenotypes via Metabolomics

  • Living reference work entry
  • First Online:
Pancreatic Cancer

Abstract

Metabolomics, one of the latest omics’ technologies, focuses on the global, quantitative, and simultaneous measurement of endogenous metabolites in a biological sample. Investigation of either individual metabolites, a panel of metabolites, or a broad metabolite profile (metabolome) can be carried out in cells, tissues, or body fluids. Recent publications indicate that there is an enormous, constantly growing multitude of metabolomics applications in oncology. As a translational research tool, metabolomics provides a link between basic in vitro laboratory data to in vivo preclinical results and clinical oncology and enables systems biology insights. In the present chapter, the current and potential future applications of metabolomics in PDAC research are focused on the clinical aspects of diagnostics.

Peter McGranaghan and Ulrike Rennefahrt contributed equally to this manuscript.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–83.

    Article  CAS  PubMed  Google Scholar 

  2. Fiehn O. Metabolomics – the link between genotypes and phenotypes. Plant Mol Biol. 2002;48(1–2):155–71.

    Article  CAS  PubMed  Google Scholar 

  3. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26(1):51–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fernie AR, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat Rev Mol Cell Biol. 2004;5(9):763–9.

    Article  CAS  PubMed  Google Scholar 

  6. van der Greef J, Smilde AK. Symbiosis of chemometrics and metabolomics: past, present, and future. J Chemom. 2005;19(5–7):376–86.

    Article  Google Scholar 

  7. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455(7216):1054–6.

    Article  CAS  PubMed  Google Scholar 

  8. Bothwell JH, Griffin JL. An introduction to biological nuclear magnetic resonance spectroscopy. Biol Rev. 2011;86(2):493–510.

    Article  PubMed  Google Scholar 

  9. Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol. 2003;7(5):648–54.

    Article  CAS  PubMed  Google Scholar 

  10. Defernez M, Colquhoun IJ. Factors affecting the robustness of metabolite fingerprinting using 1 H NMR spectra. Phytochemistry. 2003;62(6):1009–17.

    Article  CAS  PubMed  Google Scholar 

  11. Büscher JM, Czernik D, Ewald JC, Sauer U, Zamboni N. Cross-platform comparison of methods for quantitative metabolomics of primary metabolism. Anal Chem. 2009;81(6):2135–43.

    Article  PubMed  Google Scholar 

  12. Bennett BD, Yuan J, Kimball EH, Rabinowitz JD. Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach. Nat Protoc. 2008;3(8):1299–311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Perera RM, Bardeesy N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. 2015;5(12):1247–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Prim. 2015;2:16022.

    Article  Google Scholar 

  15. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149(3):656–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, Nicholls AW, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011;6(7):1060–83.

    Article  CAS  PubMed  Google Scholar 

  17. Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, Shockcor J, Loftus N, Holmes E, Nicholson JK. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc. 2013;8(1):17–32.

    Article  CAS  PubMed  Google Scholar 

  18. Kamlage B, Maldonado SG, Bethan B, Peter E, Schmitz O, Liebenberg V, Schatz P. Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin Chem. 2014;60(2):399–412.

    Article  CAS  PubMed  Google Scholar 

  19. Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci. 2015;112(32):E4410–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fujimura Y, Ikenaga N, Ohuchida K, Setoyama D, Irie M, Miura D, Wariishi H, Murata M, Mizumoto K, Hashizume M, Tanaka M. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. Pancreas. 2014;43(2):311–8.

    Article  CAS  PubMed  Google Scholar 

  21. Grüner BM, Winkelmann I, Feuchtinger A, Sun N, Balluff B, Teichmann N, Herner A, Kalideris E, Steiger K, Braren R, Aichler M, et al. Modeling therapy response and spatial tissue distribution of erlotinib in pancreatic cancer. Mol Cancer Ther. 2016;15(5):1145–52.

    Article  PubMed  Google Scholar 

  22. Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504(7479):296–300.

    Article  CAS  PubMed  Google Scholar 

  23. Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, Mukohara T, Nishiumi S, Azuma T, Yoshida M, Minami H. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. PLoS One. 2014;9(11):e113259.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom. 2010;24(5):613–20.

    Article  CAS  PubMed  Google Scholar 

  26. Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT, et al. Plasma metabolite biomarkers for the detection of pancreatic cancer. J Proteome Res. 2015;14(2):1195–202.

    Article  CAS  PubMed  Google Scholar 

  27. Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol. 2013;20(3):415–23.

    Article  Google Scholar 

  28. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22(4):571–9.

    Article  CAS  Google Scholar 

  29. Sakai A, Suzuki M, Kobayashi T, Nishiumi S, Yamanaka K, Hirata Y, Nakagawa T, Azuma T, Yoshida M. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Biomark Med. 2016;10(6):577–86.

    Article  CAS  PubMed  Google Scholar 

  30. Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, Kakuyama S, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics. 2010;6:518–28.

    Article  CAS  Google Scholar 

  31. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, Mattivi F, Latiano A, Andriulli A, Vrhovsek U, Pazienza V. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7(5):5815–29.

    PubMed  PubMed Central  Google Scholar 

  32. Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11(2):1274–83.

    Article  CAS  PubMed  Google Scholar 

  33. Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, González Maldonado S, Pilarsky C, Heidecke CD, Schatz P, Distler M, Scheiber JA, Mahajan UM, Weiss FU, Grützmann R, Lerch MM. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2017 Jan 20. pii: gutjnl-2016-312432. doi: 10.1136/gutjnl-2016-312432.

    Google Scholar 

  34. Leichtle AB, Ceglarek U, Weinert P, Nakas CT, Nuoffer J-M, Kase J, et al. Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics. 2013;9(3):677–87.

    Article  CAS  PubMed  Google Scholar 

  35. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78–95.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013;19(18):4983–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Fontana A, Copetti M, Di Gangi IM, Mazza T, Tavano F, Gioffreda D, Mattivi F, Andriulli A, Vrhovsek U, Pazienza V. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Oncotarget. 2016;7(8):8968–78.

    PubMed  PubMed Central  Google Scholar 

  38. Raftery MD, Asiago VM, Owusu-sarfo K, Xi B, Inventors, Purdue Research Foundation, Assignee. Identification of blood based metabolite biomarkers of pancreatic cancer. United States patent application US 14/465,535. 2015 Feb 26.

    Google Scholar 

  39. Pastural E, Ritchie S, Inventors, Phenomenome Discoveries Inc., Assignee. Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis. United States patent application US 13/499,369. 2010 Oct 1.

    Google Scholar 

  40. Reszka R, Kamlage B, Kalthoff H, Schniewind B, Mayerle J, Lerch MM, Pilarsky C, Grützmann R, Inventors, Metanomics Health GmbH, Assignee. Means and methods for diagnosing pancreatic cancer in a subject. United States patent application US 14/361,460. 2012 Nov 29.

    Google Scholar 

  41. Park WG, Pasricha PJ, Peltz G, Lowe A, Inventors, The Board of Trustees of the Leland Stanford Junior University, Assignee. Biomarkers for distinguishing benign, pre-malignant, and malignant pancreatic cysts. United States patent application US 14/180,892. 2014 Aug21.

    Google Scholar 

  42. Fernández-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL. Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg. 2003;138(4):427–34.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Muniraj T, Chari ST. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012;58(4):331–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, De Andrade M, Petersen GM. Pancreatic cancer–associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  46. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014;20(9):2279–303.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Guillaumond F, Bidaut G, Ouaissi M, Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet O, Pinault M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proc Natl Acad Sci. 2015;112(8):2473–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, Jin W, Mochizuki A, Goodenowe DB. Pancreatic cancer serum biomarker PC-594: diagnostic performance and comparison to CA19-9. World J. Gastroenterol: WJG. 2015;21(21):6604–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Kamlage B, Reszka R, Peter E, Kastler J, Schatz P, Kalthoff H, Schniewind B, Mayerle J, Lerch M, Pilarsky C, Grützmann R, Inventors, Metanomics Health GmbH, Assignee. Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel. WO/2015/091962. 2015 June 25.

    Google Scholar 

  50. Kell DB. Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today. 2006;11(23):1085–92.

    Article  CAS  PubMed  Google Scholar 

  51. Wheelock CE, Wheelock ÅM, Kawashima S, Diez D, Kanehisa M, van Erk M, et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol BioSyst. 2009;5(6):588–602.

    Article  CAS  PubMed  Google Scholar 

  52. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009;35(2):165–76.

    Article  CAS  PubMed  Google Scholar 

  53. Balog J, Sasi-Szabó L, Kinross J, Lewis MR, Muirhead LJ, Veselkov K, Mirnezami R, Dezső B, Damjanovich L, Darzi A, Nicholson JK. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med. 2013;5(194):194ra93.

    Article  PubMed  Google Scholar 

  54. Droste P, Weitzel M, Wiechert W. Visual exploration of isotope labeling networks in 3D. Bioprocess Biosyst Eng. 2008;31(3):227–39.

    Article  CAS  PubMed  Google Scholar 

  55. Sauer U. Metabolic networks in motion: 13C-based flux analysis. Mol Syst Biol. 2006;2:62.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hollywood K, Brison DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics. 2006;6(17):4716–23.

    Article  CAS  PubMed  Google Scholar 

  57. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 2007;4(10):828–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metanomics Health, Tegeler Weg 33, 10589, Berlin, Germany

    Peter McGranaghan, Ulrike Rennefahrt, Beate Kamlage, Regina Reszka, Philipp Schatz & Bianca Bethan

  2. Klinik für Innere Medizin A, Universitaetsmedizin der Ernst-Moritz-Arndt-Universitaet Greifswald, Ferdinand-Sauerbruch-Strasse, 17475, Greifswald, Germany

    Julia Mayerle & Markus M. Lerch

  3. Medizinische Klinik II, Klinikum der Universitaet Muenchen-Großhadern, Marchioninistraße 15, 81377, Muenchen, Germany

    Julia Mayerle

Authors
  1. Peter McGranaghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrike Rennefahrt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beate Kamlage
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Regina Reszka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philipp Schatz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bianca Bethan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Julia Mayerle
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Markus M. Lerch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus M. Lerch .

Editor information

Editors and Affiliations

  1. Div. Surgery & Oncology, University of Liverpool, Liverpool, United Kingdom

    John P. Neoptolemos

  2. Rochester, Minnesota, USA

    Raul Urrutia

  3. Dept. Gastrointestinal Medical Onco, Duke University Medical Center Dept. Gastrointestinal Medical Onco, Durham, North Carolina, USA

    James Abbruzzese

  4. Heidelberg, Germany

    Markus W. Büchler

Section Editor information

  1. Division of Surgery and Oncology, University of Liverpool, Daulby Street, Liverpool, UK

    John Neoptolemos

  2. Mayo Clinic Cancer Center, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Raul A. Urrutia

  3. Duke University Medical Center, Durham, NC, USA

    James L. Abbruzzese

  4. Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany

    Markus W. Büchler MD

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media LLC

About this entry

Cite this entry

McGranaghan, P. et al. (2016). Approaching Pancreatic Cancer Phenotypes via Metabolomics. In: Neoptolemos, J., Urrutia, R., Abbruzzese, J., Büchler, M. (eds) Pancreatic Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6631-8_61-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6631-8_61-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-6631-8

  • Online ISBN: 978-1-4939-6631-8

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation